Analyst Research Report Snapshot

Title:

MEDIVIR - FIRST DAA COMBO STUDY

Price:

$10.00

Provider:

Edison Investment Research

Date:

12 Dec 2011

Pages:

2

Type:

AcrobatPDF

Companies referenced:

MVIRb.ST

Available for Immediate Download
Summary:

The recent collaboration that allows J&J to evaluate TMC435 in combination with daclatasvir, an investigational anti-HCV compound from BMS, represents a material positive change in the prospects for the Medivir-licensed drug. Furthermore, this seems – for the time being – to have been ignored by the stock market. In our view, the deal confirms that J&J still intends to find a place for TMC435 as a part of a direct acting antiviral (DAA) combination and that this has not been affected by recent M&A or competitive developments in the HCV space.

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.